Donate

Bioverativ Officially Spins-Off of Biogen鈥檚 Hemophilia Business

February 1, 2017

Note: The following is an edited version of a press release from Bioverativ.聽Read the press release from聽Bioverativ聽in it’s entirety聽here. Today, February 1, 2017, Bioverativ聽launched as an independent, global biotechnology company focused on the discovery, development, and commercialization of innovative therapies for hemophilia and other rare blood disorders. Bioverativ is formed by a spin-off of Biogen鈥檚 […]

Arsia and Biogen Team Up to Develop Sub-Q Hemophilia Treatment

December 16, 2015

Note: The following is an edited press release from Arsia Therapeutics, Inc. The original release can be read here. Arsia Therapeutics, Inc., a Cambridge based company, announced a collaboration with Biogen on December 16, 2015. Arsia and Biogen will focus on providing meaningful treatment administration improvements for hemophilia patients by enabling subcutaneous versions of treatments […]

Biogen鈥檚 Hemophilia Therapy Donation Now Available to Patients in Developing World

October 12, 2015

Note: This is an edited form of a press release from Biogen. To read the original release in its entirety,聽click here. The first shipments of much-needed hemophilia therapy have started to arrive at treatment centers across the developing world聽Biogen,聽Swedish Orphan Biovitrum AB聽(Sobi) and the World Federation of Hemophilia (WFH) announced on Monday, October 12, 2015. […]

New Data Supports Safety & Efficacy Claims of ALPROLIX

August 17, 2015

Note: This is an edited form of a press release from Biogen. To read the original release in its entirety, click here.聽 New clinical data support the long-term safety and efficacy of ALPROLIX庐 [Coagulation Factor IX (Recombinant), Fc Fusion Protein] in people with severe hemophilia B treated for up to two years, Biogen announced on […]

New Data Supports Safety & Efficacy of ELOCTATE

August 11, 2015

Note: This is an edited version of a press release from Biogen. To read the original release, click here. _____________________________________ Newly published clinical data demonstrate that people on extended-interval prophylaxis regimens with ELOCTATE庐 [Antihemophilic Factor (Recombinant), Fc Fusion Protein] experienced low bleeding rates, Biogen and Swedish Orphan Biovitrum AB (Sobi) announced on Monday, August 10, […]

Biogen Idec and Sobi See Progress in Pediatric Hemophilia B Study

February 27, 2015

This is an edited version of a press release from Biogen Idec. To read the full release, please聽click here. ____________________ Biogen Idec聽 and聽Swedish Orphan Biovitrum聽AB announced positive top-line results of the Kids B-LONG Phase 3 clinical study that evaluated the safety, efficacy and pharmacokinetics of ALPROLIX庐聽[Coagulation Factor IX (Recombinant), Fc Fusion Protein] in children under […]

Biogen Idec Forms Partnership to Focus on Gene Therapy for Hemophilia

January 30, 2015

Biogen Idec, Fondazione Telethon, and Ospedale San Raffaele have entered into a worldwide collaboration to jointly develop gene therapies for the treatment of both hemophilia A and B. The agreement will combine聽San Raffaele – Telethon Institute for Gene Therapy鈥檚 (TIGET)聽extensive expertise in creating new gene therapy strategies and developing them from the bench to bedside […]

Biogen and MicroHealth Launch Digital Health App

September 24, 2014

Micro8 is a secure application that may help the Hemophilia A community manage infusion schedules and track bleeding episodes, and may help clinicians stay updated on their patients鈥 care. Micro8 provides mobile app, text- messaging and web-based tracking options for individuals and caregivers, who have historically logged infusions and bleeding episodes on paper or have […]

Baxter Reports Success in Long-Acting Hemophilia Product

August 23, 2014

This article was originally published in Reuters on August 21, 2014. Click here to read it in its entirety. ______________________ Baxter International Inc said a more potent version of its flagship blood disorder drug Advate met the main goal in a late-stage study. The experimental drug, BAX 855, was being tested as a preventive therapy […]

FDA Approves Biogen Idec’s ELOCATE鈩, First Long Lasting Hemophilia A Therapy

June 6, 2014

鈥 Only Hemophilia A Therapy to Provide Bleeding Protection with Prophylactic Infusions Every Three to Five Days 鈥 鈥 Approval of Biogen Idec鈥檚 Second Innovative Hemophilia Therapy with Prolonged Circulation This Year 鈥 Biogen Idec (NASDAQ: BIIB) announced that the U.S. Food and Drug Administration (FDA) has approved ELOCTATE鈩 [Antihemophilic Factor (Recombinant), Fc Fusion Protein] […]

Biogen’s Hemophilia Drug Meets Late-stage Trial Goal

October 4, 2012

(Reuters) – Biogen Idec Inc said on Wednesday its experimental treatment for patients with hemophilia B, a rare inherited blood disorder that impairs coagulation, met the main goal of controlling bleeding in a late-stage trial. A single injection of the long-lasting clotting factor, being developed in partnership with Swedish Orphan Biovitrum, controlled bleeding in 90.4 […]


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.